552c7ae14ClaimYounger patients should receive priority when lifesaving treatment is scarceAgreeDisagree2
552c7ae14ClaimThe Trump administration announced 100% tariffs on brand-name drugs with carveouts for certain categoriesAgreeDisagree
552c7ae14ClaimMedical marijuana was reclassified as Schedule III in a historic federal policy shiftAgreeDisagree
552c7ae14ClaimMultiple former FDA officials described a mass exodus following Trump administration cuts to the agencyAgreeDisagree
552c7ae14ClaimFTC reached a settlement with CVS over PBM insulin price manipulation practicesAgreeDisagree
552c7ae14ClaimThe FDA should regulate health-tracking smart rings as medical devices — debated regarding consumer wellness devices versus medical oversight scopeAgreeDisagree
552c7ae14ClaimBoston Scientific and McKesson were hit by cyberattacks exposing vulnerabilities in healthcare data securityAgreeDisagree
552c7ae14ClaimThe Justice Department prosecuted over half a billion dollars in healthcare and COVID fraud schemesAgreeDisagree
552c7ae14ClaimThe FDA moved to close the GRAS loophole allowing food additives without federal notificationAgreeDisagree
552c7ae14Claim100% tariffs on imported medicines will lower domestic drug prices without causing shortages — debated regarding trade policy impact on pharmaceutical supply chainsAgreeDisagree
552c7ae14ClaimParents should be allowed to select embryos against adult-onset inherited diseaseAgreeDisagree
552c7ae14ClaimMedicare coverage of anti-obesity drugs would add about $35 billion to federal spending from 2026 to 2034AgreeDisagree
552c7ae14ClaimSemaglutide carries a regulator-confirmed risk of NAION, a very rare optic nerve conditionAgreeDisagree
552c7ae14ClaimSemaglutide and tirzepatide are cost-effective for obesity at current net pricesAgreeDisagree
552c7ae14ClaimMost adults with obesity but without diabetes stop GLP-1 drugs within a yearAgreeDisagree